|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial显示文摘AIM: To investigate efficacy and safety of cetuximab combined with two chemotherapy regimens in patients with unresectable metastatic colorectal cancer (mCRC). METHODS: Randomized patients received cetuximab with 5-fluorouracil (5-FU), folinic acid (FA) and oxaliplatin (FOLFOX) 6 (arm A, n = 74) or 5-FU, FA and irinotecan (FOLFIRI) (arm B, n = 77). KRAS mutation status was determined retrospectively in a subset of tumors (n = 117). RESULTS: No significant difference was found between treatment arms A and B in the progression-free survival (PFS) rate at 9 mo, 45% vs 34%; median PFS, 8.6 mo vs 8.3 mo [hazard ratio (HR) = 1.06]; overall response rate (ORR) 43% vs 45% [odds ratio (OR) = 0.93] and median overall survival (OS), 17.4 mo vs 18.9 mo (HR = 0.98). Patients with KRAS wild-type tumors demonstrated improved PFS (HR = 0.55, P = 0.0051), OS, (HR = 0.62, P = 0.0296) and ORR (53% vs 36%) and in arm A, improved PFS (HR = 0.49, P = 0.0196), OS (HR = 0.48, P = 0.0201) and ORR (56%vs 30%), compared with patients with KRAS mutated tumors. In arm B no significant differences were found in efficacy by KRAS mutation status. Treatment in arms A and B was generally well tolerated. CONCLUSION: This study confirms that combinations of cetuximab with FOLFOX6 or FOLFIRI are effective and significantly improve clinical outcome in KRAS wild-type compared with KRAS mutated mCRC. | Janja Ocvirk Thomas Brodowicz Fritz Wrba Tudor E Ciuleanu Galina Kurteva Semir Beslija Ivan Koza Zsuzsanna Pápai Diethelm Messinger Ugur Yilmaz Zsolt Faluhelyi Suayib Yalcin Demetris Papamichael Miklós Wenczl Zrinka Mrsic-Krmpotic Einat Shacham-Shmueli Damir Vrbanec Regina Esser Werner Scheithauer Christoph C Zie-linski | 2010 | World Journal of Gastroenterology2010，16，25： | 17 |
| 2 | Has Power Shifted in the Grocery Channel?显示文摘 | Paul R. Messinger Chakravarthi Narasimhan | 1995 | Marketing Science1995，，2： | 2 |
| 3 | A research agenda for improving national Ecological Footprint accounts显示文摘 | Justin Kitzes Alessandro Galli Marco Bagliani John Barrett Gorm Dige Sharon Ede Karlheinz Erb Stefan Giljum Helmut Haberl Chris Hails Laurent Jolia-Ferrier Sally Jungwirth Manfred Lenzen Kevin Lewis Jonathan Loh Nadia Marchettini Hans Messinger Krista Mil | 2008 | Ecological Economics2008，，7： | 2 |
| 4 | Ovarian sex cord-stromal tumors, pleuropulmonary blastoma and DICER1 mutations: A report from the International Pleuropulmonary Blastoma Registry显示文摘 | Kris Ann P. Schultz M. Cristina Pacheco Jiandong Yang Gretchen M. Williams Yoav Messinger D. Ashley Hill Louis P. Dehner John R. Priest | 2011 | Gynecologic Oncology2011，，2： | 2 |
| 5 | On theCAD of profiles for cutters and helical flutes-geometricalaspects显示文摘 | KALDOR S RAFAEL A M MESSINGER D | 1988 | CIRP Annals-Manufacturing Technology1988，37，1： | 1 |
| 6 | Equilibrium temperatuer of an unheated icing surface as a function of airspeed显示文摘 | Messinger B L | 1953 | Journal of the Aeronautical Sciences1953，20，1： | 1 |
| 7 | Information and channel profits显示文摘 | Chu W Messinger P R | 1997 | Journal of retailing1997，73，： | 1 |
| 8 | On the CAD of profiles for cutters and HeliealFluteS-geometrical aspects 显示文摘 | KALDOR S RAFAEL A M MESSINGER D | 1998 | Annals of the CIRP1998，37，1： | 1 |
| 9 | Virtual worlds - past, present, and future: New directions in social computing 显示文摘 | Messinger P R Stroulia E Lyons K | 2009 | Deci- sion Support Systems2009，47，3： | 1 |
| 10 | Equilibrium temperature of an unheated icing surface as a function of air speed 显示文摘 | Messinger B L | 1953 | Journal of the Aeronautical Sciences1953，20，1： | 1 |
| 11 | Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood a- cute lymphoblastic leukemia ( ALL ) : a report from the therapeutic advances in childhood leukemia ( TACL ) consortium 显示文摘 | Messinger Y Gaynon P Raetz E | 2010 | Pediatr Blood Cancer2010，55，2： | 1 |
| 12 | Bortezomib with chemo- therapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lympho- ma (TACL) Study 显示文摘 | Messinger YH Gaynon PS Sposto R | 2012 | Blood2012，120，2： | 1 |
| 13 | Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept显示文摘 | Faradji RN Tharavanij T Messinger S | 2008 | Transplantation2008，86，12： | 1 |
| 14 | Effect of partial proteolysis and succinylation on functionality of corn germ protein isolate显示文摘 | MESSINGER J K RPONOW?J H ZEECE | | 0，，： | 1 |
| 15 | Reticulocyte hemoglobin measurement--comparison of two methods in the diagnosis of iron-restricted erythropoiesis显示文摘 | Thomas L Franck S Messinger M | 2005 | Clin Chem Lab Med2005，43，11： | 1 |
| 16 | Equilibrium temperature of an unheated icing surface as a function of air-speed显示文摘 | Messinger B L | 1953 | Journal of the Aeronautical Sciences1953，20，1： | 1 |
| 17 | Performance of urine test in patients monitored for recurrence of bladder cancer:a multicenter study in the United States显示文摘 | Messing EM Teot L Korman H Underhill E Barker E Stork B | | 0，，： | 1 |
| 18 | Potential utility of Ret-Y in the diagnosis of iron-restricted erythropoiesis 显示文摘 | Franek S Linssen J Messinger M | 2004 | Clin Chem2004，50，7： | 1 |
| 19 | Role of lymphadenectomy in the treatment of renal cell carcinoma显示文摘 | Phillips E Messing EM | | 0，，01： | 1 |
| 20 | On-treatment decline in serum HBsAg levels predicts sustained immune control 1 year post-treatment, subsequent I-IBsAg clearance in HBeAg-negative hepatitis B virus- infected patients treated with peginterferon alfa-2a 显示文摘 | Marcellin P Piratvisuth T Brunetto M Bonino F Farci P Yurdaydin C Gurel S Kapprell HP Messinger D Popescu M | 2010 | Hepatol Int2010，4，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员